DataLibraryResearch is tracking the market dynamics of the crisis in the Pharma & Healthcare industry amid lock-down changes in the supply chain.

Get detailed analysis of the COVID-19 impact on the Migraine Drugs Market

Global Migraine Drugs Market Opportunities and Forecast 2020-2027

  • DLR2590
  • 07 September, 2021
  • Pharma & Healthcare
  • Pages: 120
  • Global
Global Migraine Drugs Market, By Treatment (Abortive [Triptans, Ergot Alkaloids, Others] Prophylactic [Botulinum Toxin, Topiramate, Others], By Route Of Administration [Oral, Injectable, Others (Nasal, Spray, Transdermal, Patches)]), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy), and opportunities and forecast 2020-2027

Migraine Drugs Market Overview

A migraine is a headache that can cause severe throbbing pain or a pulsing sensation, usually on one side of the head. It's often accompanied by nausea, vomiting, and extreme sensitivity to light and sound. According to the world health Organization, Migraine most often begins at puberty, and mostly affects those aged between 35 and 45 years. It is more common in women, usually by a factor of about 2:1, because of hormonal influences.  In the coming years, the global Migraine Drugs market is estimated to witness outstanding growth because the demand for migraine drugs is rising steadily all over the world.
 
The rising prevalence of migraine among individuals of all age groups that need to be subsided with drugs is the major reason to boost the growth of the Migraine Drugs market. As per the Migraine Research Foundation, Migraine is the 3rd most prevalent illness in the world. Nearly 1 in 4 U.S. households includes someone with migraine. Amazingly, 12% of the population – including children – suffers from migraine. 18% of American women, 6% of men, and 10% of children experience migraines. In addition, the usual unhealthy food habits and hectic lifestyle of consumers across the world are the primary drivers that influence the growth of the global migraine drugs market.
 
Furthermore, the increasing population and growing awareness among consumers regarding the availability of migraine treatment drugs are key factors escalating the growth in the market. Apart from this, the development of advanced drugs by migraine drugs manufacturers is another main factor that boosting the growth of the migraine drugs market. 
 
On the contrary, side effects related to migraine drugs are a factor that hampers the growth of the market. Nevertheless, so far, there has not been any line of treatment apart from prescription drugs to subside the pain. This crucial fact creates enormous opportunities in the Migraine Drugs market.
 
Covid-19 Impact on Migraine Drugs Market
 
In addition, the current Migraine Drugs Market study offers a detailed analysis of the current COVID-19 pandemic impact on the market growth and its influence on the future growth of the Migraine Drugs Market. The recently published report demonstrates the elevation in the demand for the healthcare sector. The healthcare manufacturers have experienced long term as well as short term effect which includes supply shortages, panic buying, and stocking, regulation changes as short-term whereas approval delays and possible trend variations in consumption could be perceived as long-term impacts of COVID-19 on the health and pharmaceutical market.

The increasing need for a cure has pushed vaccine research and manufacturers to the limit. In addition to this, panic conditions have already spurred the demand for many healthcare products and services which are discussed in detail in this report. Moreover, the impact of COVID-19 on overall market revenue for the base year 2020 and its projection up to 2027 is provided in detail in this report.
 
Migraine Drugs Market Segment Overview
 
Based on Treatment, the Abortive segment has the largest share in the Migraine Drugs market.  The abortive segment is further classified into Triptans and Ergot Alkaloids and Others based on the drug class. Triptans are a family of tryptamine-based drugs used as abortive medication in the treatment of migraines and cluster headaches. Triptan drugs work like a brain chemical called serotonin. This helps quiet down overactive pain nerves. In other words, triptans reverse the changes in the brain that caused the migraine. In addition to this, here are seven different triptan medicines plus a combination drug that has a triptan and naproxen, a non-steroidal anti-inflammatory drug (NSAID). A doctor will choose one of them based on symptoms and how long headaches tend to last.
 
Migraine Drugs Market, By Treatment
  • Abortive
    • Triptans
    • Ergot Alkaloids
    • Others
  • Prophylactic
    • Botulinum Toxin
    • Topiramate
    • Others
Migraine Drugs Market, By Route Of Administration
·       Oral
·       Injectable
·       Others (Nasal, Spray, Transdermal, Patches)

Migraine Drugs Market, By Distribution Channel
·       Hospital Pharmacy
·       Retail Pharmacy 

Migraine Drugs Regional Overview

In terms of region, North America is anticipated to account for maximum share in the global Migraine Drugs market throughout the forecast period. This is primarily because of the rising healthcare investment by the private and government bodies. Besides this, increasing cases of migraine and the easy availability of specialized migraine treatment are some other key factors that escalating growth of the market in this region. The Asia Pacific is expected to emerge as a significant region in the overall Migraine Drugs market. The increasing cases of the migraine and growing expenditure for the healthcare sector by the government are some prime factors that propelling the growth of the market in this region.

Migraine Drugs Market, By Geography

·       North America (US & Canada)
·       Europe (UK, Germany, France, Italy, Spain, Russia & Rest of Europe)
·       Asia-Pacific (Japan, China, India, Australia, & South Korea, & Rest of Asia-Pacific)
·       LAMEA (Brazil, Saudi Arabia, UAE & Rest of LAMEA)
 
Migraine Drugs Market Competitor overview

Some key developments and strategies adopted by manufacturers in Migraine Drugs are highlighted below.

·       In September 2021, Impel NeuroPharma’s new tackle delivering an outdated migraine drug received FDA approval, giving sufferers a faster-acting manner to reply to debilitating migraine assaults. The Impel product, Trudhesa, is a nasal spray formulation of the migraine drug dihydroergotamine mesylate (DHE). The regulatory determination covers acute therapy of migraine, with or without aura, in adults.

Migraine Drugs Market, Key Players

·       Novartis AG
·       GlaxoSmithKline plc.
·       Allergan Plc.
·       Avanir Pharmaceuticals, Inc.
·       Janssen Pharmaceutical Company
·       Eisai Co.
·       Abbott Laboratories
·       AstraZeneca
·       Endo International Plc.
·       Impax Laboratories
·       Johnson & Johnson
·       Merck & Co.
·       Pfizer Inc.

Migraine Drugs Market Study Global Market Analysis, Insights and Forecast, 2020-2027

    1. Introduction

    • 1.1. Research Scope
    • 1.2. Market Segmentation
    • 1.3. Research Methodology
    • 1.4. Definitions and Assumptions

    2. Executive Summary

      3. Market Dynamics

      • 3.1. Market Drivers
      • 3.2. Market Restraints
      • 3.3. Market Opportunities

      4. Key Insights

      • 4.1. Key Emerging Trends – For Major Countries
      • 4.2. Latest Technological Advancement
      • 4.3. Regulatory Landscape
      • 4.4. Industry SWOT Analysis
      • 4.5. Porters Five Forces Analysis

      5. Global Migraine Drugs Market Analysis (USD Billion), Insights and Forecast, 2020-2027

      • 5.1. Key Findings / Summary
      • 5.2. Market Analysis, Insights and Forecast – By Treatment
        • 5.2.1. Abortive
          • 5.2.1.1. Triptans
          • 5.2.1.2. Ergot Alkaloids
          • 5.2.1.3. Others
        • 5.2.2. Prophylactic
          • 5.2.2.1. Botulinum Toxin
          • 5.2.2.2. Topiramate
          • 5.2.2.3. Others
    • 5.3. Market Analysis, Insights and Forecast – By Route Of Administration
      • 5.3.1. Oral
      • 5.3.2. Injectable
      • 5.3.3. Others (Nasal, Spray, Transdermal, Patches)
    • 5.4. Market Analysis, Insights and Forecast – By Distribution Channel
      • 5.4.1. Hospital Pharmacy
      • 5.4.2. Retail Pharmacy
    • 5.5. Market Analysis, Insights and Forecast – By Region
      • 5.5.1. North America
      • 5.5.2. Europe
      • 5.5.3. Asia Pacific
      • 5.5.4. Latin America, Middle East and Africa
    • 6. North America Migraine Drugs Market Analysis (USD Billion), Insights and Forecast, 2020-2027

      • 6.1. Key Findings / Summary
      • 6.2. Market Analysis, Insights and Forecast – By Treatment
        • 6.2.1. Abortive
          • 6.2.1.1. Triptans
          • 6.2.1.2. Ergot Alkaloids
          • 6.2.1.3. Others
        • 6.2.2. Prophylactic
          • 6.2.2.1. Botulinum Toxin
          • 6.2.2.2. Topiramate
          • 6.2.2.3. Others
    • 6.3. Market Analysis, Insights and Forecast – By Route Of Administration
      • 6.3.1. Oral
      • 6.3.2. Injectable
      • 6.3.3. Others (Nasal, Spray, Transdermal, Patches)
    • 6.4. Market Analysis, Insights and Forecast – By Distribution Channel
      • 6.4.1. Hospital Pharmacy
      • 6.4.2. Retail Pharmacy
    • 6.5. Market Analysis, Insights and Forecast – By Country
      • 6.5.1. U.S.
      • 6.5.2. Canada
    • 7. Europe Migraine Drugs Market Analysis (USD Billion), Insights and Forecast, 2020-2027

      • 7.1. Key Findings / Summary
      • 7.2. Market Analysis, Insights and Forecast – By Treatment
        • 7.2.1. Abortive
          • 7.2.1.1. Triptans
          • 7.2.1.2. Ergot Alkaloids
          • 7.2.1.3. Others
        • 7.2.2. Prophylactic
          • 7.2.2.1. Botulinum Toxin
          • 7.2.2.2. Topiramate
          • 7.2.2.3. Others
    • 7.3. Market Analysis, Insights and Forecast – By Route Of Administration
      • 7.3.1. Oral
      • 7.3.2. Injectable
      • 7.3.3. Others (Nasal, Spray, Transdermal, Patches)
    • 7.4. Market Analysis, Insights and Forecast – By Distribution Channel
      • 7.4.1. Hospital Pharmacy
      • 7.4.2. Retail Pharmacy
    • 7.5. Market Analysis, Insights and Forecast – By Country
      • 7.5.1. UK
      • 7.5.2. Germany
      • 7.5.3. France
      • 7.5.4. Italy
      • 7.5.5. Spain
      • 7.5.6. Russia
      • 7.5.7. Rest of Europe
    • 8. Asia Pacific Migraine Drugs Market Analysis (USD Billion), Insights and Forecast, 2020-2027

      • 8.1. Key Findings / Summary
      • 8.2. Market Analysis, Insights and Forecast – By Treatment
        • 8.2.1. Abortive
          • 8.2.1.1. Triptans
          • 8.2.1.2. Ergot Alkaloids
          • 8.2.1.3. Others
        • 8.2.2. Prophylactic
          • 8.2.2.1. Botulinum Toxin
          • 8.2.2.2. Topiramate
          • 8.2.2.3. Others
    • 8.3. Market Analysis, Insights and Forecast – By Route Of Administration
      • 8.3.1. Oral
      • 8.3.2. Injectable
      • 8.3.3. Others (Nasal, Spray, Transdermal, Patches)
    • 8.4. Market Analysis, Insights and Forecast – By Distribution Channel
      • 8.4.1. Hospital Pharmacy
      • 8.4.2. Retail Pharmacy
    • 8.5. Market Analysis, Insights and Forecast – By Country
      • 8.5.1. China
      • 8.5.2. India
      • 8.5.3. Japan
      • 8.5.4. Australia
      • 8.5.5. South East Asia
      • 8.5.6. Rest of Asia Pacific
    • 9. Latin America, Middle East and Africa Migraine Drugs Market Analysis (USD Billion), Insights and Forecast, 2020-2027

      • 9.1. Key Findings / Summary
      • 9.2. Market Analysis, Insights and Forecast – By Treatment
        • 9.2.1. Abortive
          • 9.2.1.1. Triptans
          • 9.2.1.2. Ergot Alkaloids
          • 9.2.1.3. Others
        • 9.2.2. Prophylactic
          • 9.2.2.1. Botulinum Toxin
          • 9.2.2.2. Topiramate
          • 9.2.2.3. Others
    • 9.3. Market Analysis, Insights and Forecast – By Route Of Administration
      • 9.3.1. Oral
      • 9.3.2. Injectable
      • 9.3.3. Others (Nasal, Spray, Transdermal, Patches)
    • 9.4. Market Analysis, Insights and Forecast – By Distribution Channel
      • 9.4.1. Hospital Pharmacy
      • 9.4.2. Retail Pharmacy
    • 9.5. Market Analysis, Insights and Forecast – By Country
      • 9.5.1. Brazil
      • 9.5.2. Saudi Arabia
      • 9.5.3. UAE
      • 9.5.4. Rest of LAMEA
    • 10. Competitive Analysis

      • 10.1. Company Market Share Analysis, 2018
      • 10.2. Key Industry Developments
      • 10.3. Company Profile
      • 10.4. Novartis AG
        • 10.4.1. Business Overview
        • 10.4.2. Segment 1 & Service Offering
        • 10.4.3. Overall Revenue
        • 10.4.4. Geographic Presence
        • 10.4.5. Recent Development
      *Similar details will be provided for the following companies
      • 10.5. GlaxoSmithKline plc.
      • 10.6. Allergan Plc.
      • 10.7. Avanir Pharmaceuticals, Inc.
      • 10.8. Janssen Pharmaceutical Company
      • 10.9. Eisai Co.
      • 10.10. Abbott Laboratories
      • 10.11. AstraZeneca
      • 10.12. Endo International Plc.
      • 10.13. Impax Laboratories
      • 10.14. Johnson & Johnson
      • 10.15. Merck & Co.
      List of Figures

      Figure 1: Global Migraine Drugs Market Revenue Breakdown (USD Billion, %) by Region, 2019 & 2027
      Figure 2: Global Migraine Drugs Market Value Share (%), By Segment 1, 2019 & 2027
      Figure 3: Global Migraine Drugs Market Forecast (USD Billion), by Sub-Segment 1, 2016-2027
      Figure 4: Global Migraine Drugs Market Forecast (USD Billion), by Sub-Segment 2, 2016-2027
      Figure 5: Global Migraine Drugs Market Value Share (%), By Segment 2, 2019 & 2027
      Figure 6: Global Migraine Drugs Market Forecast (USD Billion), by Sub-Segment 1, 2016-2027
      Figure 7: Global Migraine Drugs Market Forecast (USD Billion), by Sub-Segment 2, 2016-2027
      Figure 8: Global Migraine Drugs Market Forecast (USD Billion), by Sub-Segment 3, 2016-2027
      Figure 9: Global Migraine Drugs Market Forecast (USD Billion), by Others, 2016-2027
      Figure 10: Global Migraine Drugs Market Value Share (%), By Segment 3, 2019 & 2027
      Figure 11: Global Migraine Drugs Market Forecast (USD Billion), by Sub-Segment 1, 2016-2027
      Figure 12: Global Migraine Drugs Market Forecast (USD Billion), by Sub-Segment 2, 2016-2027
      Figure 13: Global Migraine Drugs Market Forecast (USD Billion), by Sub-Segment 3, 2016-2027
      Figure 14: Global Migraine Drugs Market Forecast (USD Billion), by Others, 2016-2027
      Figure 15: Global Migraine Drugs Market Value (USD Billion), by Region, 2019 & 2027
      Figure 16: North America Migraine Drugs Market Value Share (%), By Segment 1, 2019 & 2027
      Figure 17: North America Migraine Drugs Market Forecast (USD Billion), by Sub-Segment 1, 2016-2027
      Figure 18: North America Migraine Drugs Market Forecast (USD Billion), by Sub-Segment 2, 2016-2027
      Figure 19: North America Migraine Drugs Market Value Share (%), By Segment 2, 2019 & 2027
      Figure 20: North America Migraine Drugs Market Forecast (USD Billion), by Sub-Segment 1, 2016-2027
      Figure 21: North America Migraine Drugs Market Forecast (USD Billion), by Sub-Segment 2, 2016-2027
      Figure 22: North America Migraine Drugs Market Forecast (USD Billion), by Sub-Segment 3, 2016-2027
      Figure 23: North America Migraine Drugs Market Forecast (USD Billion), by Others, 2016-2027
      Figure 24: North America Migraine Drugs Market Value Share (%), By Segment 3, 2019 & 2027
      Figure 25: North America Migraine Drugs Market Forecast (USD Billion), by Sub-Segment 1, 2016-2027
      Figure 26: North America Migraine Drugs Market Forecast (USD Billion), by Sub-Segment 2, 2016-2027
      Figure 27: North America Migraine Drugs Market Forecast (USD Billion), by Sub-Segment 3, 2016-2027
      Figure 28: North America Migraine Drugs Market Forecast (USD Billion), by Others, 2016-2027
      Figure 29: North America Migraine Drugs Market Forecast (USD Billion), by U.S., 2016-2027
      Figure 30: North America Migraine Drugs Market Forecast (USD Billion), by Canada, 2016-2027
      Figure 31: Latin America Migraine Drugs Market Value Share (%), By Segment 1, 2019 & 2027
      Figure 32: Latin America Migraine Drugs Market Forecast (USD Billion), by Sub-Segment 1, 2016-2027
      Figure 33: Latin America Migraine Drugs Market Forecast (USD Billion), by Sub-Segment 2, 2016-2027
      Figure 34: Latin America Migraine Drugs Market Value Share (%), By Segment 2, 2019 & 2027
      Figure 35: Latin America Migraine Drugs Market Forecast (USD Billion), by Sub-Segment 1, 2016-2027
      Figure 36: Latin America Migraine Drugs Market Forecast (USD Billion), by Sub-Segment 2, 2016-2027
      Figure 37: Latin America Migraine Drugs Market Forecast (USD Billion), by Sub-Segment 3, 2016-2027
      Figure 38: Latin America Migraine Drugs Market Forecast (USD Billion), by Others, 2016-2027
      Figure 39: Latin America Migraine Drugs Market Value Share (%), By Segment 3, 2019 & 2027
      Figure 40: Latin America Migraine Drugs Market Forecast (USD Billion), by Sub-Segment 1, 2016-2027
      Figure 41: Latin America Migraine Drugs Market Forecast (USD Billion), by Sub-Segment 2, 2016-2027
      Figure 42: Latin America Migraine Drugs Market Forecast (USD Billion), by Sub-Segment 3, 2016-2027
      Figure 43: Latin America Migraine Drugs Market Forecast (USD Billion), by Others, 2016-2027
      Figure 44: Latin America Migraine Drugs Market Forecast (USD Billion), by Brazil, 2016-2027
      Figure 45: Latin America Migraine Drugs Market Forecast (USD Billion), by Mexico, 2016-2027
      Figure 46: Latin America Migraine Drugs Market Forecast (USD Billion), by Rest of Latin America, 2016-2027
      Figure 47: Europe Migraine Drugs Market Value Share (%), By Segment 1, 2019 & 2027
      Figure 48: Europe Migraine Drugs Market Forecast (USD Billion), by Sub-Segment 1, 2016-2027
      Figure 49: Europe Migraine Drugs Market Forecast (USD Billion), by Sub-Segment 2, 2016-2027
      Figure 50: Europe Migraine Drugs Market Value Share (%), By Segment 2, 2019 & 2027
      Figure 51: Europe Migraine Drugs Market Forecast (USD Billion), by Sub-Segment 1, 2016-2027
      Figure 52: Europe Migraine Drugs Market Forecast (USD Billion), by Sub-Segment 2, 2016-2027
      Figure 53: Europe Migraine Drugs Market Forecast (USD Billion), by Sub-Segment 3, 2016-2027
      Figure 54: Europe Migraine Drugs Market Forecast (USD Billion), by Others, 2016-2027
      Figure 55: Europe Migraine Drugs Market Value Share (%), By Segment 3, 2019 & 2027
      Figure 56: Europe Migraine Drugs Market Forecast (USD Billion), by Sub-Segment 1, 2016-2027
      Figure 57: Europe Migraine Drugs Market Forecast (USD Billion), by Sub-Segment 2, 2016-2027
      Figure 58: Europe Migraine Drugs Market Forecast (USD Billion), by Sub-Segment 3, 2016-2027
      Figure 59: Europe Migraine Drugs Market Forecast (USD Billion), by Others, 2016-2027
      Figure 60: Europe Migraine Drugs Market Forecast (USD Billion), by U.K., 2016-2027
      Figure 61: Europe Migraine Drugs Market Forecast (USD Billion), by Germany, 2016-2027
      Figure 62: Europe Migraine Drugs Market Forecast (USD Billion), by France, 2016-2027
      Figure 63: Europe Migraine Drugs Market Forecast (USD Billion), by Italy, 2016-2027
      Figure 64: Europe Migraine Drugs Market Forecast (USD Billion), by Spain, 2016-2027
      Figure 65: Europe Migraine Drugs Market Forecast (USD Billion), by Russia, 2016-2027
      Figure 66: Europe Migraine Drugs Market Forecast (USD Billion), by Rest of Europe, 2016-2027
      Figure 67: Asia Pacific Migraine Drugs Market Value Share (%), By Segment 1, 2019 & 2027
      Figure 68: Asia Pacific Migraine Drugs Market Forecast (USD Billion), by Sub-Segment 1, 2016-2027
      Figure 69: Asia Pacific Migraine Drugs Market Forecast (USD Billion), by Sub-Segment 2, 2016-2027
      Figure 70: Asia Pacific Migraine Drugs Market Value Share (%), By Segment 2, 2019 & 2027
      Figure 71: Asia Pacific Migraine Drugs Market Forecast (USD Billion), by Sub-Segment 1, 2016-2027
      Figure 72: Asia Pacific Migraine Drugs Market Forecast (USD Billion), by Sub-Segment 2, 2016-2027
      Figure 73: Asia Pacific Migraine Drugs Market Forecast (USD Billion), by Sub-Segment 3, 2016-2027
      Figure 74: Asia Pacific Migraine Drugs Market Forecast (USD Billion), by Others, 2016-2027
      Figure 75: Asia Pacific Migraine Drugs Market Value Share (%), By Segment 3, 2019 & 2027
      Figure 76: Asia Pacific Migraine Drugs Market Forecast (USD Billion), by Sub-Segment 1, 2016-2027
      Figure 77: Asia Pacific Migraine Drugs Market Forecast (USD Billion), by Sub-Segment 2, 2016-2027
      Figure 78: Asia Pacific Migraine Drugs Market Forecast (USD Billion), by Sub-Segment 3, 2016-2027
      Figure 79: Asia Pacific Migraine Drugs Market Forecast (USD Billion), by Others, 2016-2027
      Figure 80: Asia Pacific Migraine Drugs Market Forecast (USD Billion), by China, 2016-2027
      Figure 81: Asia Pacific Migraine Drugs Market Forecast (USD Billion), by India, 2016-2027
      Figure 82: Asia Pacific Migraine Drugs Market Forecast (USD Billion), by Japan, 2016-2027
      Figure 83: Asia Pacific Migraine Drugs Market Forecast (USD Billion), by Australia, 2016-2027
      Figure 84: Asia Pacific Migraine Drugs Market Forecast (USD Billion), by Southeast Asia, 2016-2027
      Figure 85: Asia Pacific Migraine Drugs Market Forecast (USD Billion), by Rest of Asia Pacific, 2016-2027
      Figure 86: Middle East & Africa Migraine Drugs Market Value Share (%), By Segment 1, 2019 & 2027
      Figure 87: Middle East & Africa Migraine Drugs Market Forecast (USD Billion), by Sub-Segment 1, 2016-2027
      Figure 88: Middle East & Africa Migraine Drugs Market Forecast (USD Billion), by Sub-Segment 2, 2016-2027
      Figure 89: Middle East & Africa Migraine Drugs Market Value Share (%), By Segment 2, 2019 & 2027
      Figure 90: Middle East & Africa Migraine Drugs Market Forecast (USD Billion), by Sub-Segment 1, 2016-2027
      Figure 91: Middle East & Africa Migraine Drugs Market Forecast (USD Billion), by Sub-Segment 2, 2016-2027
      Figure 92: Middle East & Africa Migraine Drugs Market Forecast (USD Billion), by Sub-Segment 3, 2016-2027
      Figure 93: Middle East & Africa Migraine Drugs Market Forecast (USD Billion), by Others, 2016-2027
      Figure 94: Middle East & Africa Migraine Drugs Market Value Share (%), By Segment 3, 2019 & 2027
      Figure 95: Middle East & Africa Migraine Drugs Market Forecast (USD Billion), by Sub-Segment 1, 2016-2027
      Figure 96: Middle East & Africa Migraine Drugs Market Forecast (USD Billion), by Sub-Segment 2, 2016-2027
      Figure 97: Middle East & Africa Migraine Drugs Market Forecast (USD Billion), by Sub-Segment 3, 2016-2027
      Figure 98: Middle East & Africa Migraine Drugs Market Forecast (USD Billion), by Others, 2016-2027
      Figure 99: Middle East & Africa Migraine Drugs Market Forecast (USD Billion), by GCC, 2016-2027
      Figure 100: Middle East & Africa Migraine Drugs Market Forecast (USD Billion), by South Africa, 2016-2027
      Figure 101: Middle East & Africa Migraine Drugs Market Forecast (USD Billion), by Rest of Middle East & Africa, 2016-2027 
      List of Tables
      Table 1: Global Migraine Drugs Market Revenue (USD Billion) Forecast, by Segment 1, 2016-2027
      Table 2: Global Migraine Drugs Market Revenue (USD Billion) Forecast, by Segment 2, 2016-2027
      Table 3: Global Migraine Drugs Market Revenue (USD Billion) Forecast, by Segment 3, 2016-2027
      Table 4: Global Migraine Drugs Market Revenue (USD Billion) Forecast, by Region, 2016-2027
      Table 5: North America Migraine Drugs Market Revenue (USD Billion) Forecast, by Segment 1, 2016-2027
      Table 6: North America Migraine Drugs Market Revenue (USD Billion) Forecast, by Segment 2, 2016-2027
      Table 7: North America Migraine Drugs Market Revenue (USD Billion) Forecast, by Segment 3, 2016-2027
      Table 8: North America Migraine Drugs Market Revenue (USD Billion) Forecast, by Country, 2016-2027
      Table 9: Europe Migraine Drugs Market Revenue (USD Billion) Forecast, by Segment 1, 2016-2027
      Table 10: Europe Migraine Drugs Market Revenue (USD Billion) Forecast, by Segment 2, 2016-2027
      Table 11: Europe Migraine Drugs Market Revenue (USD Billion) Forecast, by Segment 3, 2016-2027
      Table 12: Europe Migraine Drugs Market Revenue (USD Billion) Forecast, by Country, 2016-2027
      Table 13: Latin America Migraine Drugs Market Revenue (USD Billion) Forecast, by Segment 1, 2016-2027
      Table 14: Latin America Migraine Drugs Market Revenue (USD Billion) Forecast, by Segment 2, 2016-2027
      Table 15: Latin America Migraine Drugs Market Revenue (USD Billion) Forecast, by Segment 3, 2016-2027
      Table 16: Latin America Migraine Drugs Market Revenue (USD Billion) Forecast, by Country, 2016-2027
      Table 17: Asia Pacific Migraine Drugs Market Revenue (USD Billion) Forecast, by Segment 1, 2016-2027
      Table 18: Asia Pacific Migraine Drugs Market Revenue (USD Billion) Forecast, by Segment 2, 2016-2027
      Table 19: Asia Pacific Migraine Drugs Market Revenue (USD Billion) Forecast, by Segment 3, 2016-2027
      Table 20: Asia Pacific Migraine Drugs Market Revenue (USD Billion) Forecast, by Country, 2016-2027
      Table 21: Middle East & Africa Migraine Drugs Market Revenue (USD Billion) Forecast, by Segment 1, 2016-2027
      Table 22: Middle East & Africa Migraine Drugs Market Revenue (USD Billion) Forecast, by Segment 2, 2016-2027
      Table 23: Middle East & Africa Migraine Drugs Market Revenue (USD Billion) Forecast, by Segment 3, 2016-2027
      Table 24: Middle East & Africa Migraine Drugs Market Revenue (USD Billion) Forecast, by Country, 2016-2027

      Report You Might be Interested

      Choose License Type

      • USD
      • GBP
      • EURO
      • INR
      Credit card Logo

      Happy To Assist You

      Have a Question? email us at

      info@datalibraryresearch.com

      Or Call Us On

      US +1 360 851 1343

      IND +91 880 579 4934